{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:26:00Z","timestamp":1790400360582,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011684","name":"Crohn's and Colitis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cgh.2023.07.027","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T18:42:24Z","timestamp":1691865744000},"page":"499-512.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"22","author":[{"given":"Akshita","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-1821","authenticated-orcid":false,"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.07.027_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.cgh.2023.07.027_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.07.027_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl B","key":"10.1016\/j.cgh.2023.07.027_bib4","first-page":"S14","article-title":"Biologic agents in rheumatoid arthritis: an update for managed care professionals","volume":"17","author":"Agarwal","year":"2011","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.cgh.2023.07.027_bib5","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/MIB.0000000000001099","article-title":"Management of inflammatory bowel disease in the elderly patient: challenges and opportunities","volume":"23","author":"Ananthakrishnan","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2023.07.027_bib6","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1111\/j.1572-0241.1999.01530.x","article-title":"Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine","volume":"94","author":"Korelitz","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.07.027_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/gut.47.4.514","article-title":"Increased incidence of non-Hodgkin\u2019s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low","volume":"47","author":"Farrell","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.07.027_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.07.027_bib10","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.07.027_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.07.027_bib12","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib13","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2023.07.027_bib14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.07.027_bib16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00007890-199304000-00011","article-title":"The effect of immunosuppression on pre-existing cancers","volume":"55","author":"Penn","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.cgh.2023.07.027_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.cgh.2023.07.027_bib18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cgh.2023.07.027_bib19","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cgh.2023.07.027_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.crohns.2013.12.022","article-title":"Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease","volume":"8","author":"Rajca","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.07.027_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of non-melanoma skin cancer in patients with a history of NMSC with the use of immunosuppressant and biologic agents in autoimmune disease","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-eular.1134","article-title":"The influence of anti-TNF or rituximab on cancer incidence in patients with rheumatoid arthritis who have HAD a prior malignancy","volume":"73","author":"Silva-Fernandez","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.07.027_bib23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/ecco-jcc\/jjv032","article-title":"Incidence, management, and course of cancer in patients with inflammatory bowel disease","volume":"9","author":"Algaba","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.07.027_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143286","article-title":"Tumor necrosis factor inhibition and head and neck cancer recurrence and death in rheumatoid arthritis","volume":"10","author":"Phillips","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2023.07.027_bib27","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/art.39738","article-title":"Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study","volume":"68","author":"Mamtani","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2023.07.027_bib28","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","article-title":"The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis","volume":"55","author":"Silva-Fern\u00e1ndez","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2023.07.027_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/M17-2812","article-title":"Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis","volume":"169","author":"Raaschou","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2023.07.027_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cgh.2023.07.027_bib31","article-title":"Treatment of psoriasis with biologics and apremilast in patients with a history of malignancy: a retrospective chart review","volume":"18","author":"Kahn","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14309\/ajg.0000000000000210","article-title":"Immunomodulatory therapy does not increase the risk of cancer in persons with inflammatory bowel disease and a history of extracolonic cancers","volume":"114","author":"Ma\u00f1osa","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.07.027_bib33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S2468-1253(19)30362-0","article-title":"Anti-tumour necrosis factor-\u03b1 therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study","volume":"5","author":"Waljee","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib34","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/jgh.15806","article-title":"Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy","volume":"37","author":"Hasan","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib35","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.14309\/ajg.0000000000000679","article-title":"Repeated occurrences of basal cell cancer in patients with inflammatory bowel disease treated with immunosuppressive medications","volume":"115","author":"Khan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.07.027_bib36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5217\/ir.2019.09140","article-title":"Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy","volume":"18","author":"Phan","year":"2020","journal-title":"Intest Res"},{"key":"10.1016\/j.cgh.2023.07.027_bib37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cgh.2020.10.007","article-title":"Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: a retrospective cohort study","volume":"20","author":"Vedamurthy","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14889","article-title":"IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review","volume":"34","author":"Bellinato","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.cgh.2023.07.027_bib39","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ibd\/izac035","article-title":"Ustekinumab and vedolizumab are not associated with subsequent cancer in IBD patients with prior malignancy","volume":"28","author":"Hong","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2023.07.027_bib40","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/ibd.21487","article-title":"Clinical course of Crohn\u2019s disease following treatment of lymphoma","volume":"17","author":"El Mourabet","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2023.07.027_bib41","author":"Bae"},{"key":"10.1016\/j.cgh.2023.07.027_bib42","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.07.027_bib43","author":"Fagerli"},{"key":"10.1016\/j.cgh.2023.07.027_bib44","doi-asserted-by":"crossref","first-page":"S-577","DOI":"10.1016\/S0016-5085(14)62091-6","article-title":"Mo1175 thiopurines and anti-TNFs in patients with inflammatory bowel disease and a previous diagnosis of cancer","volume":"146","author":"Onali","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.07.027_bib45","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/MIB.0000000000000741","article-title":"Risk of incident cancer in inflammatory bowel disease patients starting anti-TNF therapy while having recent malignancy","volume":"22","author":"Poullenot","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2023.07.027_bib46","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/annrheumdis-2014-205745","article-title":"TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study","volume":"74","author":"Raaschou","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.07.027_bib47","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/ecco-jcc\/jjac061","article-title":"Comparative risk of incident cancer in patients with inflammatory bowel disease with prior non-digestive malignancy according to immunomodulator: a multicentre cohort study","volume":"16","author":"Poullenot","year":"2002","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.07.027_bib48","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.cgh.2023.01.002","article-title":"Comparative safety of biologic agents in patients with inflammatory bowel disease with active or recent malignancy: a multi-center cohort study","volume":"21","author":"Holmer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib49","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib50","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2023.07.027_bib51","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? A meta-analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2023.07.027_bib52","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cgh.2014.07.058","article-title":"The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a Markov model","volume":"13","author":"Scott","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2011.09.017","article-title":"Adverse events do not outweigh benefits of combination therapy for Crohn\u2019s disease in a decision analytic model","volume":"10","author":"Siegel","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.07.027_bib54","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/gutjnl-2013-305300","article-title":"The management of immunosuppression in patients with inflammatory bowel disease and cancer","volume":"62","author":"Bernheim","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.07.027_bib55","doi-asserted-by":"crossref","first-page":"S585","DOI":"10.1093\/ecco-jcc\/jjz203.857","article-title":"P729 the SAPPHIRE registry: safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a HIstoRy of CancEr","volume":"14","author":"Axelrad","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.07.027_bib57","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523006249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523006249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:44:55Z","timestamp":1761543895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523006249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1542356523006249"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.07.027","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute","name":"copyright","label":"Copyright"}]}}